NAD+ vs Sobetirome (GC-1)

Metabolic

Metabolic

Research Only

Research Only

NAD+ functions as a primary electron carrier in glycolysis, the TCA cycle, and oxidative phosphorylation. Beyond its redox role, NAD+ serves as a consumable substrate for sirtuin deacetylases (SIRT1-7), poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes. Sirtuin activation is linked to mitochondrial biogenesis, autophagy, and stress-response gene expression, and PARP activity is central to DNA-damage repair. Oral bioavailability of intact NAD+ is poor, which is why clinics market IV infusion; the best human data for raising tissue NAD+ involve oral precursors NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) rather than NAD+ itself.

Sobetirome acts as an agonist at thyroid hormone receptor beta (TRβ) with substantially reduced affinity for TRα, conferring tissue-selective thyromimetic activity. Structural features—an oxyacetic acid moiety and absence of the amino group found in T3—underlie its subtype selectivity in both binding and activation. In hypothyroid mice, this TRβ selectivity produced lipid-lowering effects comparable to T3 without the cardiac chronotropic (heart-rate) increase driven by TRα, supporting the design goal of metabolic benefit with reduced cardiac risk.